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Epidemiological and molecular 
mechanisms aspects linking 
obesity and cancer
Mecanismos epidemiológicos e moleculares 
que associam obesidade e câncer
Felipe Osório-Costa1, Guilherme Z. Rocha1, Marília M. Dias1, José B. C. Carvalheira1
AbstrAct
About 25% of cancer cases globally are due to excess weight and a sedentary lifestyle. These 
results are alarming, as the world knows a pandemy of obesity and, in consequence, insulin 
resistance. Obesity may increase risk for various cancers by several mechanisms, including 
increasing sex and metabolic hormones, and inflammation. Here, we present a review of epi-
demiological and molecular evidences linking obesity and cancer – particularly colorectal, post-
menopausal breast, endometrial, pancreatic, high grade prostate, hepatocellular, gallbladder, 
kidney and esophageal adenocarcinoma. The expected striking increase in the incidence of 
cancer in the near future related to obesity turns the knowledge of this field of great impact as 
it is needed to the development of strategies to prevent and treat this disease. Arq Bras Endocrinol 
Metab. 2009;53(2):213-226.
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resumo
Aproximadamente 25% dos casos de câncer são decorrentes do excesso de peso e do modo de 
vida sedentário. Esses resultados são alarmantes, pois o mundo vive uma pandemia de obesida-
de e, consequentemente, de resistência à insulina. A obesidade pode aumentar o risco de vários 
tipos de câncer por diversos mecanismos, incluindo aumento dos hormônios sexuais e metabó-
licos, e de inflamação. Neste trabalho, apresentamos uma revisão das evidências epidemiológi-
cas e moleculares que relacionam a obesidade ao câncer – em particular aos cânceres colorretal, 
mamário na pós-menopausa, endometrial, pancreático, prostático avançado, hepatocelular, de 
bexiga, renal e esofágico. O aumento esperado da incidência de câncer relacionado à obesidade 
em um futuro próximo torna o conhecimento dessa área de grande importância, uma vez que este 
é fundamental para o desenvolvimento de estratégias preventivas e terapêuticas para a doen ça. 
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Since the 1980’s, the world has been living a striking increase in the prevalence of overweight and obesity. 
This phenomenon has had it’s beginning in developed 
countries, but, nowadays, it is also common to many 
other populous regions over the world, as Asia and Latin 
America, and it is becoming a Public Health concern 
(1,2). By the end of the last millennium, nearly two-
thirds of adults in the United States were overweight or 
obese, and their prevalence continues to increase in this 
decade (3). The incidence of type 2 diabetes during this 
same period of time has mirrored the obesity epidemic, 
and that is presumed to be a direct result of it. 
There are epidemiologic studies linking adiposity 
and the risk of several adult cancers. Investigation of 
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tions applied to the process of excess body weight and 
carcinogenesis has, thus, become an interesting re-
search field. This review outlines the epidemiological 
and clinical evidence implicating excess body weight 
both in increased cancer risk and its impact on mortal-
ity in certain neoplasias. Some hypothesis explaining 
these epidemiological observations are explored, spe-
cially the metabolic and endocrine effects of obesity, 
and the alterations that they induce in the produc-
tion of peptide, steroid hormones and inflammation 
pathways.
epIDemIology of ADIposIty AnD cAncer rIsK 
Evidences from epidemiological studies indicate that 
adiposity contributes to an elevated risk of developing 
some cancers and may also influence disease outcomes. 
Both the International Agency for Research on Cancer 
(IARC) (4) and, more recently, the World Cancer Re-
search Fund (WCRF) (5) have concluded that, among 
the different cancer sites, this association is positive for 
esophageal adenocarcinoma, and cancers of the pancre-
as, colorectum, post-menopausal breast, endometrium 
and kidney, beyond the evidence of a probable associa-
tion with risk of gallbladder cancer.
These results were further confirmed to the high 
prevalent cancers listed above and extended to reveal 
associations with less common malignancies in a large 
British cohort, the Million Women Study, and in a mul-
tiethnic systematic review and meta-analysis (table 1). 
It is important to observe that this multiethnic analysis 
found a constant association between body mass index 
(BMI) and cancer across populations, except for pre-
menopausal breast cancer, in which there has been ob-
served a positive association with increased BMI in Asia-
Pacific populations, but an inverse association in the 
other regions (6,7). There are also some other constant 
similarities in most of the epidemiologic evidences. The 
effect of BMI on risk differed significantly according 
to menopausal status (and, by extrapolation, hormonal 
influences) as follows: increased risk in pre-menopausal 
women for colorectal cancer and malignant melanoma, 
while increased risk in post-menopausal women for breast 
and endometrial cancers (6). As a concern to intergen-
der comparisons, there are differences in associations at 
some sites, notably colon, rectum and kidney (8).
Running title: obesity & cancer
table 1. Summary of estimated trend in the relative risk of cancer incidence by type, adapted from two recent large studies (6,7). Data in italic have not reached 
significance
 British cohort Multiethnic meta-analysis 
Incident cases 45,037 282,137
Trend in relative risk per 10 kg/m2 Trend in relative risk per 5 kg/m2
Cancer site Female Female Male
Endometrium 2.89 1.59 NA
Oesophageal adenocarcinoma 2.38 1.51 1.52
Renal 1.53 1.34 1.24
Leukemia 1.50 1.17 1.08
Multiple myeloma 1.31 1.11 1.11
Non-Hodgkin lymphoma 1.17 1.07 1.06
Breast (post-menopausal) 1.4 1.12 NA
Colorectum (pre-menopausal) 1.61 NA NA
Colon NA 1.09 1.24
Rectum NA 1.02 1.09
Gallblader NA 1.59 1.09
Prostate NA NA 1.03
Pancreas 1,24 1.12 1.07
Ovary 1,14 1.03 NA
Liver NA 1.24 1.07
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excess boDy weIght AnD cAncer outcome 
Given that BMI is consistently associated with can-
cer risk at several sites, it is not surprising that increased 
adiposity may have a negative effect on treatment out-
come and ultimate survival. Data from a large Amer-
ican cohort published by Calle and cols. (9) was the 
germinal evidence that obesity may be an unfavorable 
prognostic factor in patients diagnosed with cancer. 
The heaviest members of this cohort (those with a BMI 
index of, at least, 40) had death rates from all cancers 
combined, and they were 52% higher for men, and 62% 
higher for women, than the rates in men and women of 
normal weight. These results were recently confirmed 
by Reeves and cols. (6) in another large British cohort. 
These observations in human studies are supported by 
pre-clinical data that observed different outcome in 
models of cancer. In these studies, they were worse in 
diet-induced obesity animal models (10), and better in 
energy restriction ones (11). 
obesIty relAteD cAncers
colorectal cancer 
Obesity has been associated with higher risk of colorec-
tal cancer. However, there are important differences re-
lated to gender and sites. The association between BMI 
and risk for colon cancer is positive in men, RR = 1.24, 
but the evidences are weaker in women, RR = 1.09 (8). 
Further, the association with rectal cancer is also weaker 
and present only in men, RR = 1.09.
There are some hypotheses for this gender difference. 
One of them is that central adiposity, quite more frequent 
in men, may have an important role in the pathophysi-
ology underlying the association between abdominal 
obesity and increased colon cancer risk. This could be 
expected, once abdominal obesity has been shown to be 
more strongly associated with metabolic abnormalities 
than gluteofemoral obesity (12). This hypothesis has 
been supported by epidemiological evidences that associ-
ates increased waist circumference or increased waist-hip 
ratio with colon cancer risk in men and women, whereas 
body weight and BMI are associated with colon cancer 
risk in men but not in women (13,14). By contrast to 
colon cancer risk, these anthropometric results were not 
reproduced as risk factor for rectal cancer. These epide-
miological data are supported by consistent results that 
associate insulin resistance and subsequent hyperinsu-
linemia as risk factors for colon cancer (15). 
Increased levels of bioavailable insulin-like growth 
factor (IGF)-1, which is known to have cancer promot-
ing effects, are related to hyperinsulinemia. In addition, 
insulin interacts with the axis, by reducing the synthesis 
of IGF binding proteins (IGFBP) (16). The IGF-1 sys-
tem has been linked to colorectal malignancy by a con-
vergence of data from epidemiological, clinical and lab-
oratory-based sources (16-18). Recent results have also 
implicated higher levels of prediagnosis plasma C-pep-
tide and lower levels of prediagnosis plasma IGFBP-1 
with increased mortality among patients with surgically 
resected colorectal cancer (19). These results lead to 
the hypothesis that circulating insulin and IGFBP-1 are 
potential mediators of the association between lifestyle 
factors and mortality after colorectal cancer resection.
In regard to adipose tissue-derived cytokines and hor-
mones, collectively named adipokines, recent results may 
involve them in tumourigenesis. First, leptin, whose cir-
culating levels are closely related to the amount of adipose 
tissue and is also related to insulin resistance, has been 
related to progression of colon cancer in experimental 
studies (16,20-22). This hormone conveys information 
to the brain about the size of energy storage and its levels 
are increased by overfeeding (23). In contrast, energy re-
striction, a well-established protective factor against can-
cer (24), decreases this hormone levels (24,25). In light 
of this evidence, leptin was suggested as a link between 
obesity and colon cancer. This hypothesis is supported by 
two case-control studies (22,26) that demonstrated sig-
nificant associations of leptin with colon cancer risk, but 
not rectal cancer. By contrast, adiponectin, an adipokine 
decreased in obesity, is inversely associated with the devel-
opment of insulin resistance and has a strong anti-inflam-
matory function (3). There are controversial data relating 
low plasma adiponectin levels with higher risk of colorec-
tal cancer in men, and there is need to further prospective 
studies to investigate this association (27,28). 
breast cancer 
The evidence linking obesity to breast cancer risk is 
dependent on the menopausal status. There is consis-
tent evidence for this association in post-menopausal 
women, but not in pre-menopausal ones. In fact, there 
are some registries of a modest reduction in risk among 
women with elevated BMI, which could be because of 
a tendency for these women to have anovulatory men-
strual cycles and lower levels of circulating steroid hor-
mones – notably of progesterone and estradiol. 
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In addition, studies that examined both factors have 
found that adult weight gain is generally more asso-
ciated with increase in risk of post-menopausal breast 
cancer than BMI (29); this could also be an effect of 
anovulatory menstrual cycles in the young obese wom-
en. As regards to breast cancer outcome, BMI ≥ 40 kg/
m2 is associated with higher mortality, RR = 2.12 (9). 
This worse prognosis may be because of true biological 
effect of adiposity on survival or secondary to delayed 
diagnosis in heavier women.
As concerns to sex steroids, the higher expression 
of aromatase, which produces estrogens from andro-
genic precursors, may have an important role in the 
pathophysiology underlying the association between 
post-menopausal breast cancer and cancer risk in obese 
women (8). There is convincing evidence relating the 
association of BMI with post-menopausal breast cancer 
risk to be almost entirely mediated by elevated blood 
levels of estradiol (30). These analyses also demonstrat-
ed that elevated blood concentrations of androgens are 
associated with increased risk of breast cancer in both 
pre and post-menopausal women, and, thus, androgens 
may be potential candidates linking obesity and breast 
cancer. In contrast to men, testosterone concentrations 
are positively related with obesity in women (30).
Besides steroids influences, several studies associated 
hyperinsulinemia, measured as high circulating levels of 
serum C-peptide, with elevated risk of post-menopaus-
al breast cancer (31-33), although these associations 
were inconsistent with pre-menopausal breast cancer 
(32-34). In addition, cohort studies and a meta-anal-
ysis support increased IGF-1 levels, an indirect effect 
of hyperinsulinemia, as a risk factor for pre-menopausal 
breast cancer (17,35). Furthermore, insulin resistance 
is an adverse prognostic factor for breast cancer (36). 
In regard to adipokines, a recent review from Vona-
Davis and Rose (37) has found inconsistent results related 
to leptin as breast cancer risk factor. In contrast, two case-
control studies concurrently reported inverse association 
between adiponectin and breast cancer; significant for 
both pre and post-menopausal in one (38), and for post-
menopausal women only in the other (39). Clearly, pro-
spective studies are needed to examine the role of obesity 
biomarkers in the development of breast cancer.
endometrial carcinoma 
The strongest association, 2.5-3.0-fold increase in risk, 
between obesity and cancer risk is reported to endo-
metrial carcinoma (6,8). The pathophysiology underly-
ing this association, like for breast cancer, is associated 
to estrogens exposition. This hypothesis is supported 
by epidemiological studies that have related high lev-
els of plasma estrone and estradiol as risk factors for 
endometrial cancer risk in post-menopausal women. 
In addition, hyperandrogenism may also play a cen-
tral role linking obesity to endometrial cancer risk in 
pre-menopausal women, as it leads to diminished levels 
of progesterone and continuous anovulation. The hy-
pothesis is that lack of progesterone promotes unop-
posed estrogen exposition and continuous proliferation 
stimulus to endometrial cell lines, which may increase 
the risk of endometrial cancer, whereas, in post-meno-
pausal, excess weight may continue to increase the risk 
primarily through elevated plasma levels of bioavail-
able estrogens, and secondary to higher expression 
of aromatase, in the absence of ovarian progesterone 
synthesis. Furthermore, besides a rise in estrogens and 
androgens, excess weight leads to a decrease in plasma 
sex hormone-binding globulin (40). In a multicenter 
prospective study in post-menopausal women (41), 
circulating estrogens and androgens were found to be 
positively associated with endometrial cancer risk, and 
an inverse association was reported for sex hormone-
binding globulin.
With regard to insulin resistance, it was speculated 
that elevated estrogens and low progesterone promote 
increase in IGF-1 bioactivity within endometrial tissue, 
resulting from estrogen-induced IGF-1 synthesis and 
reductions in IGFBP-1, leading to the development 
and growth of endometrial tumours (40). In addition, 
biomarkers of hyperinsulinemia, as C-peptide, have 
been shown to be associated with increased endome-
trial cancer risk (42). 
renal cancer 
There are several evidences that link obesity as a risk fac-
tor for renal cell cancer (12,43). Most of them found 
a dose-response relationship with increasing weight or 
BMI (44). However, few studies have observed that fat 
distribution does not predict renal cell cancer risk beyond 
adiposity in general (45). As regards to gender, there is 
an unexplained difference with stronger association in 
women than in men (44).
Hypertension and diabetes, both of which are risk fac-
tors for renal cell cancer, are also associated with obesity 
(12,46). However, some evidence suggested that obesity 
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increases the risk of renal cell cancer even independently 
of blood pressure levels, indicating that hypertension and 
obesity might influence renal cell cancer through differ-
ent mechanisms (12). 
The pathophysiology underlying the association of 
obesity and renal cell cancer remains unclear. Very re-
cently, lower adiponectin levels were observed in individ-
uals with renal cell cancer when compared with healthy 
controls (47). There is clearly a need for additional stud-
ies of this issue with a larger number of patients. 
esophageal and gastric carcinoma 
There is a marked change in esophageal and gastric car-
cinomas epidemiology. Whereas the incidence rates of 
esophageal adenocarcinoma and gastric cardia have ris-
en in recent decades, they remained stable for esopha-
geal squamous cell carcinoma and have declined steadily 
for noncardia gastric adenocarcinoma (48). This rise in 
incidence has partly been attributed to the rise in the 
prevalence of obesity. Some evidence from cohorts and 
meta-analysis have recently confirmed the association 
between obesity and risk of esophageal adenocarcinoma 
(6,7,49). Regarding the risk for gastric cardia adenocar-
cinoma in this analysis, a high BMI was weakly associ-
ated with the risk of cardia adenocarcinoma (RR = 1.5). 
Recently, these results were reinforced by a large Ameri-
can cohort, which has found an increased risk for gastric 
cardia adenocarcinoma for people with BMI ≥ 35 kg/
m2. In contrast, there has not been found any associa-
tion with gastric non-cardia adenocarcinoma (50). 
Thus, there is impressive evidence to link obesity as 
a risk factor for esophageal and gastric cardia cancer. 
However, BMI does not explain the intergender dif-
ferences found in the incidence rates of these cancers, 
which are more frequent in white men than in women. 
One hypothesis is that abdominal obesity could explain 
this discordance. A recent case-control study exam-
ined the distribution of obesity as a risk factor for these 
types of cancer and has found strongly association be-
tween elevated abdominal diameter and increased risk 
of esophageal adenocarcinoma. However, this associa-
tion was not confirmed with the risk of gastric cardia 
adenocarcinomas (51). Further prospective studies are 
necessary to confirm this hypothesis. 
At present, Barrett’s esophagus, characterized by 
replacement of squamous epithelium with columnar 
epithelium, is the most common cause of esopha-
geal adenocarcinoma. The pathophysiology of Bar-
rett’s esophagus involves gastroesophageal reflux 
and esophagitis (52). Further, obesity is related to 
esophagitis, and this association is not present only in 
symptomatic gastroesophageal reflux obese individuals. 
The exact role that obesity plays within these processes 
remains to be defined.
pancreatic carcinoma 
For some time, there was controversy between the link 
of obesity and pancreatic carcinoma. Early case-control 
studies have found weak association, but this is believed 
to have been biased because of high mortality or reli-
ance on proxy interviews (53). A considerable number 
of prospective studies and meta-analysis have examined 
this subject during the last years (9,54), and have shown 
positive results (13). Recently, this results were rein-
forced by The Women’s Health Initiative in The United 
States, which has found a 70% excess risk of pancreatic 
cancer for women in the highest quintile of waist-to-hip 
ratio compared with women in the lowest quintile (55). 
Several evidence implicates hyperinsulinemia and hy-
perglycemia in the pathophysiology of pancreatic cancer 
(56). However, as it matters to IGF axis, a nested case-
control study within four large cohort studies has not 
found associations between pre-diagnostic plasma levels 
of IGF-1, IGF-2 and IGFBP-3 and pancreatic cancer 
risk (57). The exact role that obesity and insulin resis-
tance play within these processes remains to be defined.
prostate cancer 
Epidemiological evidence is conflicting and has failed to 
show overall significant associations between obesity and 
the risk of prostate cancer (4), although a meta-analysis 
has suggested a weak significant positive association, with 
an estimated increase in prostate cancer risk of 1.05 per 
5 kg/m2 (58). However, concerning to prostate cancer 
outcomes, there is convincing evidence which indicates 
that obese men with prostate cancer are more likely to 
have aggressive disease that recurs after radical prostatec-
tomy than non-obese men (59). 
Some studies have positively associated high IGF-1 
circulating levels with prostate cancer risk, whereas total 
IGFBP-3 levels were negatively associated (60). There 
is clearly a need for additional studies of this issue with a 
larger number of patients to examine the possible effects 
of obesity and insulin resistance in the pathophysiology 
of pancreatic cancer. 
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hepatocellular and gallbladder cancer 
The relationship between obesity and risk of gallblad-
der cancer has recently been investigated in some me-
ta-analyses and cohort studies (6,7,61). Most of them 
have found a dose-response relationship with increas-
ing weight or BMI (RR = 1.15 in those who were over-
weight, and RR = 1.66 in those who were obese). The 
risk was stronger for women (RR = 1.88) than for men 
(RR = 1.35). The mechanisms by which obesity may af-
fect gallbladder cancer risk are unclear until now. How-
ever, gallstone formation is a major risk factor for this 
disease and obesity is one of the factors that increase 
gallstone formation. 
Obesity as well as type 2 diabetes are also likely to be 
risk factors for hepatocellular cancer (62). It is suggested 
that the increase in the incidence of non-alcoholic fatty 
liver disease could be the underlying mechanism related 
to the recent increase in risk for hepatocellular carcinoma, 
once it may progress to steatohepatitis and cirrhosis. 
other cAncers
lung cancer 
Several studies reported an inverse association between 
obesity and lung cancer, although this data may be sec-
ondary to confounding effects of smoking. However, 
in non-smoking populations, there has not been found 
any association to link obesity as a risk factor for lung 
cancer (9,63).
cervical carcinoma 
The literature is exiguous about the association be-
tween obesity and cervical cancer. Overall there is no 
association reported (28), however an American case-
control study found an increased risk of adenocarcino-
mas of the cervix, not extensive to squamous cell carci-
nomas of the cervix (RR = 1.6) (64). Clearly, additional 
studies of this issue with a larger number of patients are 
needed to investigate the association between obesity 
and cervical cancer.
ovarian cancer 
A recent systematic review has found a weak (1.3-fold) 
increase association between obesity and risk for ovar-
ian cancer (65). It was speculated that the association 
between obesity and weight gain could be restricted to 
some subtypes of ovarian cancer, but this hypothesis 
was not confirmed in an Australian case-control study, 
which has found no association with BMI or weight 
gain for any of the histological subtypes (66). These re-
sults add to the current evidence that obesity increases 
a woman’s risk of developing distinct histological sub-
types of ovarian cancer.
hematopoietic neoplasias 
Several evidence from meta-analysis or large cohort 
studies have found weak association between obesity 
and lymphohaematopoietic cancers, including lympho-
mas, acute and chronic leukaemia (67) and multiple 
myeloma (6,7,68). Further prospective studies of this 
issue with a larger number of patients are needed to 
examine the possible role of obesity as a risk factor for 
hematopoietic neoplasias.
summAry of epIDemIologIcAl evIDence
After reviewing a large number of literatures, there is 
currently sufficient evidence that obesity increases the 
risk for esophageal adenocarcinoma, and cancers of the 
pancreas, colorectum, post-menopausal breast, endo-
metrium and kidney, beyond evidence of a probable 
association with risk of gallbladder cancer and hepa-
tocellular cancer. The more recently published stud-
ies suggest that obesity may also increase the risk of 
advanced-stage prostate cancer. It is also suggested that 
obesity is a risk factor for hematopoietic neoplasias. 
However, this association may be weak, and there is 
need for further studies to explore the molecular mech-
anisms of obesity that could explain these results. 
proposeD mechAnIsms
endogenous hormones 
The association between excess body weight with 
cancer risk may be explained by alterations in the me-
tabolism of endogenous hormones – including insulin, 
insulin-like growth factors and sex steroids – which can 
lead to distortion of the normal balance between cell 
proliferation, differentiation, and apoptosis. However, 
the pathophysiological and biological mechanisms un-
derpinning these associations are only starting to be 
understood. 
Tumour genesis occurs as a result of mutations that 
confer a set of cancer-specific hallmarks, including self-
sufficiency in growth signals and evasion of apoptosis. 
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Many cancer-causing genes encode protein kinases; in-
deed, the protein kinase domain is the most commonly 
found functional domain known in cancer genes. As 
protein kinases occupy apical positions in signal-trans-
duction cascades, integrate with many other signal-
ing pathways and regulate the activity or abundance 
of transcription factors, the cellular effects of aberrant 
protein kinases activity are wide-ranging. 
The functional importance of this acquired capabil-
ity for the manifestation of the disease has been further 
validated by the approval of tyrosine kinase inhibitors 
as cancer therapeutics – most notably the ones target-
ing the BCR Abl and cKIT signaling pathways. The 
pioneer of the clinical proof-of-concept for tyrosine 
kinase inhibitors is Imatinib (Gleevec, Novartis) tar-
geting the BCR Abl and cKIT receptor (69). Imatinib 
has been approved for treating patients with chronic 
myeloid leukemia and gastrointestinal stromal tumor. 
Numerous ongoing clinical trials seek to expand the ap-
plications of each of tyrosine kinase pathway inhibitors, 
and dozens of other tyrosine kinase inhibitors are being 
clinically evaluated. 
The same is true for endogenous hormones signal-
ing, which integrates with others signal-transduction 
cascades to control a variety of processes – including 
gene expression. Recent years have seen a growing ap-
preciation of the extent to which components of en-
dogenous hormones are remodeled or deregulated in 
cancer. Whether these changes are drivers that are re-
quired to sustain the transformed phenotype remains 
to be established. In this section, we review the core 
components of the endogenous hormones signaling 
systems, focusing on the role of insulin, insulin-like 
growth factor and sex steroids in one crucial aspect of 
the cancer phenotype – control of cell proliferation.
Insulin and insulin-like growth factor 
In the early 1990’s, McKeown-Eyssen (70) and Gio-
vannucci (71) noted that the risk factors for Western-
ized cancer were remarkably similar to those for insulin 
resistance, and suggested that hyperinsulinemia might 
contribute to cancer development through the growth-
promoting effect of elevated levels of insulin. In addi-
tion to its importance in glucose homeostasis, it is well 
established that insulin is a crucial hormone in anabolic 
processes involved in early growth and development, 
and may be also a strong mediator of the adverse effect 
of obesity on cancer prognosis. 
Excess body weight, increased plasma triglyceride 
levels, low levels of physical activity and certain dietary 
patterns can all favor elevated circulating insulin levels. 
Chronically increased insulin concentrations reduce the 
synthesis of IGFBP-1 and 2, resulting in increased levels 
of free, IGF-1 Bio-Active®, and concomitant changes in 
the cellular environment, that favor tumor development 
(72). It is also suggested that IGF-1 can synergize with 
other growth factors to produce enhanced mitogenic 
effects, and may operate via an endocrine, paracrine or 
autocrine manner to regulate cell growth, cell survival, 
cell transformation, and cell differentiation. 
Growth hormone (GH) provides the main stimulus 
for the synthesis of IGF-1 in liver, which is the source 
of over 80% of circulating IGF-1, and nutritional en-
ergy balance exerts profound and complex effects on 
the synthesis and biological activity of IGF-1. In type 
1 diabetes patients, or in chronically fasting people, the 
low production of insulin, which causes a reduction in 
hepatic GH-receptor levels, also results in GH resistance 
and reduction of IGF-1 blood levels and synthesis. The 
IGF-1 bioavailability to tissue receptor is also reduced 
by the increased levels of IGFBP-1 and IGFBP-2. On 
the other hand, patients with type 2 diabetes, or in over 
nourished states, have high levels of endogenous insu-
lin and hepatic GH-receptor, producing large amounts 
of IGF-1 (73). Paradoxically, however, obese people 
have lower blood levels of IGF-1 than normal-weight, 
well-nourished individuals (21). Recent studies have 
shown a non-linear relationship between IGF-1 and 
anthropometric indices of adiposity, with the highest 
levels of IGF-1 at a BMI of around 24-27 kg/m2, and 
lower levels for men and women in either the lower or 
higher BMI categories (74,75). An explanation for the 
low IGF-1 blood levels in obese individuals, despite in-
creased GH sensitivity of liver and other tissues, is that 
reductions in IGFBP-1 and IGFBP-2 levels increase 
the negative feedback by free IGF-1 on pituitary GH 
secretion, resulting in reduced synthesis of IGF-1 and 
reduced plasma IGF-1 concentrations (21).
Many in vitro and in vivo models provide convinc-
ing evidence for a role of IGF-1 receptor (IGF-1R) in 
different forms of cancer. Initial in vitro experiments 
demonstrated that increasing IGF-1 concentrations in-
duced a dose-dependent increase in human breast can-
cer cell proliferation (76). In vivo models using muta-
tions associated with low IGF-1 levels or reduced ligand 
levels showed that in vivo tumour growth is influenced 
by the IGF-1 physiology of the host (77,78). The work 
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by Creighton and cols. (79) showed that a pattern of 
gene expression induced by IGF-1 represents pathways 
of increased aggressiveness and possibly hormone inde-
pendence in clinical breast cancers.
As shown in Figure 1, both insulin and IGF-1 acti-
vate the important tyrosine kinase growth receptor path-
way, insulin receptor (IR) and IGF-1R, respectively, as 
well as the hybrid IGF-1/IR – all of which are expressed 
at higher levels in malignant cells and resistant to down-
regulation typical of receptors in nonmalignant cells 
exposed to insulin (80). Activation of these receptors 
results in up-regulation of insulin response substrate-1 
(IRS-1), leading to downstream activation of the mito-
genic-activated protein (MAP) kinase pathway and the 
phosphoinositide-3 kinase/Akt (PI3K-Akt) pathway – 
two of the most important signaling cascades frequently 
deregulated in cancer. In addition, there is accumulating 
evidence that these pathways may cooperate to promote 
the survival of transformed cells (81). 
PI3K is recruited to the membrane after stimulation 
by various different growth factors and cytokines. At 
this site, the enzyme is activated and, in proximity to its 
lipid substrate, phosphatidylinositol (4,5)-bisphosphate 
[PtdIns(4,5)P2], generates PtdIns(3,4,5)P3 (82). The 
tumor suppressor PTEN acts reversing the action of 
PI3K, dephosphorylating PtdIns(3,4,5)P3 and is thus 
an essential suppressor of PI3K signaling. This PTEN 
function is lost in various advanced-stage cancers. Effec-
tor proteins with pleckstrin-homology (PH) domains, 
such as the AKT/PKB and 3-phosphoinositide-depen-
dent protein kinase 1 (PDK1) protein kinases, utilizes 
PtdIns(3,4,5)P3 as a docking site. PKB phosphorylates 
various substrates involved in diverse processes, includ-
ing cell survival (inactivation of the proapoptotic protein 
BAD), glycogen synthesis (down-regulation of glycogen 
synthase kinase-3) and gene transcription (FOXO tran-
scription factors) (82); however, PKB also promotes cell 
and organism growth downstream of PI3K. The mech-
anisms indicating how the insulin-PI3K-PKB pathway 
induces growth has recently been clarified by the finding 
that PKB phosphorylates and inactivates (83) tuberin 
– also known as tuberous sclerosis complex 2 (TSC2) –, 
an inhibitor of cell growth, thereby inactivating the 
function of the TSC1-TSC2 tumour suppressor com-
plex. TSC1-TSC2 is a complex of the proteins hamartin 
(TSC1) and tuberin (10) that acts inhibiting GTPase-
activating protein activity of the small GTPase, Rheb 
(84). Activation of PI3K induced by insulin has been 
shown to relieve this inhibitory activity (84), resulting in 
activation of Rheb. This induction of Rheb leads to acti-
vation of the mTOR pathway and an mTOR-regulated 
serine/threonine kinase, S6K.
figure 1. The insulin/IGF-1 receptor is a tyrosine kinase that undergoes autophosphorylation, and catalyses the phosphorylation of cellular proteins such as members of the 
IRS family and Shc. Upon tyrosine phosphorylation, these proteins interact with signaling molecules through their SH2 domains, resulting in a diverse series of signaling 
pathways, including activation of PI(3)K and downstream PtdIns(3,4,5)P3-dependent protein kinases, ras and the MAP kinase cascade. These pathways act in a concerted 
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The signaling through mTOR pathway is important 
in ribosome biogenesis and cell growth (85), and its in-
duction after PI3K activation and inactivation of TSC1-
TSC2 by PKB might explain the sequential activation of 
PKB and S6K by insulin (86). As recently shown, phos-
phorylation of tuberin by the p90 ribosomal S6 kinase 1 
(Rsk1) (87) has a similar inhibitory effect to that of PKB 
on TSC1-TSC2, this way promoting mTOR signaling; 
however, phosphorylation of tuberin by 5’ AMP-acti-
vated protein kinase (AMPK) in response to reduced 
cellular energy levels might act in the opposite manner 
to regulate TSC1-TSC2 function positively (88).
Cellular growth is controlled in part by mTOR-
raptor which phosphorylates the hydrophobic motif of 
S6K1, activating this kinase. mTOR-raptor also phos-
phorylates and inhibits 4E-BPs, proteins that inhibit the 
eIF4E-dependent translation of capped mRNAs (85). 
Persuasive evidence suggests the existence of a nega-
tive-feedback loop that enables the nutrient-sensitive 
mTOR-raptor pathway, through S6K1, to desensitize 
insulin signaling (89). S6K1 mediates the feedback by 
phosphorylating and inactivating IRS1. 
The MAP kinase-Ras-Raf cascade is centrally impor-
tant in driving tumor cell proliferation. The Ras/Raf/
MEK/ERK cascade couples signals from cell surface 
receptors to transcription factors, which regulate gene 
expression. Furthermore, this cascade also regulates the 
activity of many proteins involved in apoptosis.
The Raf gene family consists of three proteins, 
termed A-Raf, B-Raf and Raf-1 (C-Raf). Raf is a serine/
threonine (S/T) kinase, normally activated by a com-
plex series of events, including: (i) interaction with Ras 
and subsequent recruitment to the plasma membrane; 
(ii) dimerization of Raf proteins; (iii) phosphorylation/
dephosphorylation on different domains; (iv) disasso-
ciation from the Raf kinase inhibitory protein (RKIP), 
and (v) association with scaffolding complexes (e.g., 
kinase suppressor of Ras, (KSR). Chaperonin proteins 
such as Bag1, 14-3-3 (90) and heat shock protein 90 
(Hsp90) modulates Raf activity (91).
When activated, Raf phosphorylates the serine resi-
due in the activation loop of Mek (MAPKK) (92). The 
activated Mek1/2 phosphorylates the MAPK protein, 
ERK, on adjacent threonine and tyrosine residues. 
Active ERK phosphorylates multiple cytoplasmic and 
cytoskeletal proteins (93), including MAPK-activated 
protein kinases and the family of approximately 90-kDa 
ribosomal S6 kinases (Rsk). Additionally, active ERK 
and Rsk1/2 translocate to the nucleus, where ERK 
phosphorylates and activates various transcription fac-
tors, such as Sp1, E2F, Elk-1 and AP-1 (94). AP-1 is 
comprised of two short-lived proteins, Jun and Fos, 
which are the product of immediate early genes (IEGs). 
This pathway can control various cellular processes such 
as proliferation, migration and differentiation.
Part of insulin and IGF-1 action is also mediated by 
the crosstalk of these pathways with that of the estro-
gen receptor pathway in breast cells.
sex steroids
With regard to sex steroids, adiposity influences the 
synthesis and bioavailability of the hormones through, 
at least, three mechanisms. First, adipose tissue express-
es a variety of sex-steroid-metabolizing enzymes, like 
aromatase, that promote the formation of estrogens 
from androgenic precursors, which are secreted by the 
gonads or adrenal glands. Adipose tissue is the major 
site of estrogen synthesis in men and postmenopausal 
women, with levels of aromatase and circulating levels 
of estrone and estradiol strongly related to BMI (95). 
A second hypothesis is that obesity results in an in-
crease in circulating levels of insulin and IGF-1 bioactiv-
ity. Insulin and IGF-1 both inhibit the synthesis of sex 
hormone-binding globulin (SHBG) – the major carrier 
protein for testosterone and estradiol in the plasma – 
and may lead to an increase in the amount of unbound 
sex-steroid available for bioactivity (96). In one study, 
obese women (BMI > 30 kg/m2) had average SHBG 
concentration that was half of that of women with a 
BMI of < 22 kg/m2 (97).
SHBG can act directly on breast cancer cells inhibit-
ing the cell proliferation induced by estradiol. Binding 
of this protein to cell membrane induces the second 
messenger cAMP on MCF-7 breast cancer cell line 
(98), and leads to a complete inhibition of estradiol-
induced cell proliferation (99). In addition, the pre-
incubation of MCF-7 cells with SHBG before estradiol 
treatment counteracts the antiapoptotic effect of the 
hormone (100). Thus, SHBG prevents estradiol action 
in breast cancer cells, acting as an anti-proliferative fac-
tor, loss of which could contribute to tumorigenesis in 
obese women. 
Estradiol (E2) and IGFs also act as mitogens in breast 
cancer cells trough the activation of ERalpha transcrip-
tional activity. They act together and reciprocally. In addi-
tion, insulin at supraphysiologic doses may reproduce the 
IGF-1 effects on breast cells. It was shown in breast can-
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cer cell lines that E2 interacts with the whole transduction 
pathways of IGF (101). IGFs act through two membrane 
receptors: IGF-1R and type 2 receptors (IGF-2R). How-
ever, most of the effects of IGFs are mediated by the IGF-
1R. Activation by the ligand leads to an autophospho-
rylation and binding to signaling adaptor proteins, like 
insulin receptor substrate (IRS)-1 and Shc, which activate 
the ERK and PI3Kinase pathways.
Finally, high insulin levels can increase ovarian, and 
possibly also adrenal, androgen synthesis, and can cause 
the development of the polycystic ovary syndrome in 
some genetically susceptible pre-menopausal women 
(102). PCOS is characterized by ovarian hyperandro-
genism and chronic anovulation, which results in con-
tinuous estrogen stimulation of the endometrium unop-
posed by progesterone (103). In PCOS pre-menopausal 
women, ovarian hyperandrogenism likely increases risk 
of endometrial cancer by decreasing local uterine IG-
FBP-1 synthesis, which in turn increases bio-availability 
of IGF-1, favoring tumor formation (104). Polycystic 
ovary syndrome and obesity are both associated with 
increased risk of endometrial cancer in pre and post-
menopausal women, respectively (73,105), and share 
mechanistic pathways that overlap between the estro-
gen, progesterone, androgen, and IGF systems.
Breast cancer risk and most established risk factors 
for endometrial cancer, such as early menarche, late 
menopause and obesity, probably act through pathways 
reflecting greater life-time exposure to estrogens. At a 
molecular level, estrogen actions are mediated by the es-
trogen receptors (ERalpha or ERbeta). The ER genomic 
actions involve its role as a transcription factor by binding 
directly to DNA through estrogen response elements, 
or by tethering to DNA through interaction with other 
proteins. However, estrogen can also exhibit pleiotropic 
effects trough nongenomic interactions with growth fac-
tor signaling pathways, including the phosphatidylinosi-
tol 3-kinase (PI3K)/Akt and the mitogenic-activated 
protein kinase pathways (106). Thus, besides ER is pre-
dominantly localized in the nucleus in steroid-deprived 
MCF-7 breast cancer cells, a substantial proportion is 
translocated to the plasma membrane upon E2 stimula-
tion, contributing to growth factor receptor signaling. 
obesity inflammation and cancer 
A causal relationship between cancer and inflammation 
is suspected for thousands of years. Galen was the first to 
note the relationship and Virchow, in the 19th century, 
demonstrated that leukocytes were present in malignant 
tissues, claiming that tumors arise from chronic inflam-
mation sites (107). Chronic infection and the consecutive 
inflammation that occurs may affect normal tissue cells, 
transforming these cells and might even affect tumors 
cells trough interaction with surrounding cells. Cancer 
deaths (15%-20%) can be linked to inflammation and 
infection. For example, the major risk factors for hepa-
tocellular carcinoma (HCC) are hepatitis B virus (HBV) 
and hepatitis C virus (HCV) chronic infections, and most 
gastric cancers are associated with Helicobacter pylori in-
fections (108). Ulcerative colitis and other inflammatory 
bowel diseases are thought to increase the risk of col-
orectal cancer (109), and irritation and inflammation of 
airways by airborne particles and tobacco smoke might 
be important promoters of lung carcinogenesis (110). 
In parallel, there is a large amount of evidence that 
links obesity, inflammation and the development of in-
sulin resistance (111,112). In obese adipose tissue there 
is macrophage recruitment, which, in turn, results in a 
pro-inflammatory state. Macrophages that are infiltrat-
ed in other tissues are known to secrete large amounts 
of tumor-necrosis factor (TNF), leading to a chronic 
inflammatory state with impaired triglyceride deposi-
tion and increased lipolysis, the excess of circulating 
triglyceride and free fatty acids results in disruption of 
normal metabolic functions such as mitochondrial oxi-
dative phosphorylation and insulin-stimulated glucose 
transport, thus triggering insulin resistance.
Serine phosphorylation of IRS are major mechanisms 
that suppresses the insulin pathway leading to insulin 
resistance (113). In this regard, JNK, a member of the 
MAP kinase family that can be activated by TNFalpha, 
might serve as a feedback inhibitor during insulin stim-
ulation. JNK activation induces inhibitory serine 307 
(Ser307) phosphorylation of IRS-1. Ser307 is located 
next to the phosphotyrosine-binding (PTB) domain in 
IRS-1 and its phosphorylation inhibits the interaction of 
the PTB domain with the phosphorylated NPEY motif 
in the activated IR, causing insulin resistance (114). Pre-
vious studies suggest that, in addition to JNK, IKKbeta 
phoshorylation also increases serine phosphorylation of 
IRS-1. Thus, the IKK complex appears to be another 
candidate that plays a key role in the phosphorylation of 
IRS-1 and in the regulation of insulin sensitivity. 
The nuclear factor kappaB (NF-kappaB) pathway 
plays a central role in inflammation and immunity. 
Transcription factors, which integrate stress signals 
and orchestrate immune responses known as NF-
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kappaB proteins, have recently been linked to the 
hallmarks of carcinogenesis, and recent experimental 
studies have demonstrated the mechanistic pathways 
by which NF-kappaB signaling (Figure 2) and JNK 
contributes to these aspects (115,116). Greten and 
cols. (115) utilized the IKKbeta conditional knockout 
to test the role of the NF-kappaB activation pathway 
in controlling tumorigenesis in a colitis-associated 
model for cancer. In another related study, Maeda and 
cols. (116) showed that loss of IKKbeta in hepato-
cytes actually promoted chemical-induced hepatocar-
cinogenesis through a mechanism involving enhanced 
ROS production and JNK activation with associated 
cell death, leading to a compensatory response in sur-
viving hepatocytes.
The consistent results from epidemiologic studies 
linking adiposity and the risk of several adult cancers 
turns plausible the hypothesis that the molecular mech-
anisms of carcinogenesis may be mediated by inflam-
matory pathways. In face of the striking prevalence of 
obesity, understanding the exact molecular mechanisms 
connecting the two may be crucial to the treatment of 
this pathology. 
conclusIon
In several studies, obesity has been associated with risk 
and prognosis for various cancers, and several mecha-
nisms have been proposed to explain the links between 
obesity and cancer. Confirmation of the role of obe-
sity on cancer risk and prognosis has emerged from 
clinical trials and meta-analyses in the last decades. Im-
provement of the knowledge of the pathophysiological 
mechanisms linking obesity and cancer would be neces-
sary to establish Public Health interventions for reduc-
ing the impact of cancer.
Disclosure: No potential conflict of interest relevant to this article 
was reported.
figure 2. Activation of tumour-necrosis factor receptor 1 (TNFR) by binding of TNFα results in rapid assembly of complex I, which is composed of TNF receptor 1-associated 
protein (TRADD), receptor-interacting protein 1 (RIP1). This complex leads to activation of inhibitor of NFκB kinase (IKK). Activation of IKK leads to IκB phosphorylation and 
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